InMed Pharmaceuticals - Progress across the business
With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is...
560 Views
InMed Pharmaceuticals - NM-755 Phase II about to begin
In the coming weeks, InMed expects to begin patient enrolment in a Phase II (755-201-EB) trial for INM-755 in up to 20 epidermolysis bullosa (EB)...
1.2k Views
InMed Pharmaceuticals - Acquiring BayMedica
InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the...
1.4k Views
InMed Pharmaceuticals - INM-755 trial full enrollment expected this quarter
InMed Pharmaceuticals recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of...
593 Views
InMed Pharmaceuticals - Developing cannabinol (CBN)
InMed has announced that the cannabinoid that is the basis for both its epidermolysis bullosa (EB) and glaucoma programs is cannabinol (CBN). This...
742 Views